Placebo response in antipsychotic clinical trials: a meta-analysis. - Wikidata - wikimedia - TriplyDB

Placebo response in antipsychotic clinical trials: a meta-analysis.

Placebo response in antipsychotic clinical trials: a meta-analysis.

http://www.wikidata.org/entity/Q34443837

about

The role of inflammation in schizophrenia Manipulating the Placebo Response in Experimental Pain by Altering Doctor's Performance Style What can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general?Placebo Response in Repetitive Transcranial Magnetic Stimulation Trials of Treatment of Auditory Hallucinations in Schizophrenia: A Meta-Analysis.Certainty of genuine treatment increases drug responses among intellectually disabled patients.Placebo Responses in Genetically Determined Intellectual Disability: A Meta-Analysis.Placebo eff ects in psychiatry: mediators and moderators.Factors Influencing the Placebo Effect in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: An Analysis of Two Randomized Clinical Trials A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia.Practising evidence-based medicine in an era of high placebo response: number needed to treat reconsidered.INFLUENCE OF STUDY DESIGN ON TREATMENT RESPONSE IN ANXIETY DISORDER CLINICAL TRIALS Predictors of placebo response in pharmacological and dietary supplement treatment trials in pediatric autism spectrum disorder: a meta-analysis The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis.Methodological issues associated with preclinical drug development and increased placebo effects in schizophrenia clinical trials.D-cycloserine in Schizophrenia: New Strategies for Improving Clinical Outcomes by Enhancing Plasticity.Mechanisms of the placebo effect in pain and psychiatric disorders.Short-term open-label chamomile (Matricaria chamomilla L.) therapy of moderate to severe generalized anxiety disorder.Managing Negative Symptoms of Schizophrenia: How Far Have We Come?Increasing placebo response in antipsychotic trials: a clinical perspective.Clinical Trials to Gain FDA Approval for Computerized Cognitive Training: What Is the Ideal Control Condition?Specific expectancies are associated with symptomatic outcomes and side effect burden in a trial of chamomile extract for generalized anxiety disorder.Blinded sample size re-estimation in three-arm trials with 'gold standard' design.Methods for assessing and controlling placebo effects.A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Tocilizumab, An Interleukin-6 Receptor Antibody, For Residual Symptoms in Schizophrenia.A Machine Learning Approach to Identifying Placebo Responders in Late-Life Depression Trials.[Non-invasive brain stimulation for treatment of schizophrenic psychoses].Failed efficacy of ziprasidone in the treatment of post-traumatic stress disorder.Recruitment and retention strategies in mental health trials - A systematic review

P2860

Q26779719-2A39374D-D10D-41C8-AF61-F96C54738852 Q27304510-D301AC1A-AAEE-401C-8EAD-A44CEF48B02C Q28083481-E9217D99-9575-471D-92BB-CE393E5995EB Q30711964-58005705-462F-4CD5-B33B-E78AA623FAE3 Q33726997-5CB28E81-2CE7-4E21-8741-60DA8C86175E Q34487591-AE063B28-EE64-48CE-A825-C997ED44EC5C Q35207492-2EE760C9-A1A9-45A1-83B4-B833632E9372 Q36038231-436521B2-C622-4A4E-9256-504FDB24D1D8 Q36475355-920EC51F-B3D0-421F-B846-01585F99B9EF Q36859704-87D594C3-6205-4400-92AF-FD5343168A50 Q37041164-DBFDD7B0-1E55-4717-BAB6-F259B4FF8A40 Q37347743-D6078175-BFDF-4BA0-B9F2-E96E8225F6B1 Q38672790-0A6912D4-EDAB-4033-89F8-6BDD3CEC06A3 Q38676860-5AD0477C-AC59-49C6-BAE8-9FA3C69A082A Q38750121-B7780654-F2BF-4FA2-A96E-15EE2B5CFBEE Q38784077-23223291-9DCA-41C6-8C96-10812EA266D2 Q38787906-D2A82D58-F1A9-4D46-8938-5665AB773D55 Q39233330-0D1D3D6B-0737-460C-931D-16223709C795 Q40783366-A1F0AB8C-E869-41FB-A3A2-29BCE1D3D465 Q41643206-C8589D89-E158-4672-89B6-9828FF6D5C38 Q47149850-B4088E3F-9705-47A4-9A39-B35380681CC0 Q47206643-45E678C7-7BA2-4B5A-AC71-59F562451863 Q47248824-6BC665B4-6A1E-4FDC-B018-94832F8F9845 Q47579231-CE103A58-4DA7-492C-9D2C-751980835DDE Q49342341-118B41A2-8F12-4E42-8F02-226B0ADAE48A Q53360993-3998E146-E651-4770-8795-4ADE4AAE53B0 Q55313130-03E1EAF0-65BA-4521-928D-E321092E4CDC Q58695939-CCE21FB2-0659-4EFB-A8E6-098AF77D4A3A

P2860

Placebo response in antipsychotic clinical trials: a meta-analysis.

http://www.wikidata.org/entity/Q34443837

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

Placebo response in antipsychotic clinical trials: a meta-analysis.

@ast

Placebo response in antipsychotic clinical trials: a meta-analysis.

@en

Placebo response in antipsychotic clinical trials: a meta-analysis.

@nl

type

label

Placebo response in antipsychotic clinical trials: a meta-analysis.

@ast

Placebo response in antipsychotic clinical trials: a meta-analysis.

@en

Placebo response in antipsychotic clinical trials: a meta-analysis.

@nl

prefLabel

Placebo response in antipsychotic clinical trials: a meta-analysis.

@ast

Placebo response in antipsychotic clinical trials: a meta-analysis.

@en

Placebo response in antipsychotic clinical trials: a meta-analysis.

@nl

P1433

Q34443837-9BF1AB85-6476-4BFB-9E16-1878549FC480

P1476

Q34443837-66773829-0E07-4129-9019-35B4907B7F17

P2093

Q34443837-0034D968-F969-4C4C-8D43-AFC5FB589A3A

Q34443837-06BD82A9-5175-41CB-9037-C38FD2738AE7

Q34443837-2DD8572E-DAE3-4C2D-A79D-A1B168EC7289

Q34443837-A6EEE359-2C2C-4727-A516-12E2B96CAA26

Q34443837-B5B14C41-8005-4889-A624-249419F51728

Q34443837-D12899A4-1569-44CC-B28F-5EF4B831080A

P2860

Q34443837-0230AEB2-AD03-4E8D-B5D8-D2CBD6A3AE41

Q34443837-066F1133-8166-40BA-95AB-A7B969173C99

Q34443837-0700C00F-CABE-46CB-BE21-55708AE29254

Q34443837-08AF13C5-C47F-4019-B1C3-325CE506A1BD

Q34443837-0ADFF290-6AA6-486A-9022-CA145DD44E15

Q34443837-0F525642-C3E3-4288-9127-6B8F210CD107

Q34443837-1221AA17-C5E4-4C1D-A59F-F63387F8B99D

Q34443837-17C00D0E-819C-46E1-946A-BACF590A969A

Q34443837-1C5B591B-931B-4ECC-BDD8-78A2980C0C7F

Q34443837-1D927291-ACEB-46E6-A7E6-AD6CB4AF3279

P304

Q34443837-155DFA24-8D68-4B61-B1F9-884C2BBB2CF6

P31

Q34443837-682F5408-BA22-43EF-9973-F85369DB39DE

Q34443837-b2804474-9552-4f13-883a-4483763faccc

P356

Q34443837-25395C87-293E-465C-972E-EFF67A66B5C2

P407

Q34443837-7A3D7D03-73BB-441A-82E3-D0B03C6FD3D2

P433

Q34443837-2EBC9488-944F-4975-8A73-5FA7470B46EA

P478

Q34443837-B53D7257-F34F-4A77-B30A-64F5F8F26909

P577

Q34443837-712D843F-55AF-403F-9838-B67A93B983E1

P5875

Q34443837-C3360CAE-A9BF-4572-95F4-7C825FA995D4

P698

Q34443837-D445DAA7-A124-417C-AAD5-4EE106801427

P921

Q34443837-8AF40D4F-3E97-464E-89EC-D8A7E358959E

Q34443837-DF599E8E-D7A9-4C74-90BC-CD6AD0CCDADE

P932

Q34443837-273D0730-1A6B-4969-A372-2D2D71EBF79A

P356

JAMAPSYCHIATRY.2014.1319

P1433

JAMA Psychiatry

P1476

Placebo response in antipsychotic clinical trials: a meta-analysis.

@en

P2093

Bret R Rutherford

http://www.w3.org/2001/XMLSchema#string

Emily Pott

http://www.w3.org/2001/XMLSchema#string

Jane M Tandler

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Lieberman

http://www.w3.org/2001/XMLSchema#string

Melanie M Wall

http://www.w3.org/2001/XMLSchema#string

Steven P Roose

http://www.w3.org/2001/XMLSchema#string

P2860

Quantifying heterogeneity in a meta-analysis

Controlled trial of sulpiride in chronic schizophrenic patients

Double-blind therapeutic evaluation of fluspirilene compared with fluphenazine decanoate in chronic schizophrenics

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group.

Clinic visits in late-life depression trials: effects on signal detection and therapeutic outcome.

Cognitive behavioral psychotherapy for schizophrenia: a review of recent empirical studies.

Placebo response in studies of major depression: variable, substantial, and growing.

A double-blind controlled trial of pipotiazine, haloperidol and placebo in recently-hospitalized acute schizophrenic patients.

Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations.

Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study.

P304

1409-1421

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMAPSYCHIATRY.2014.1319

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266975123

http://www.w3.org/2001/XMLSchema#string

P698

25321611

http://www.w3.org/2001/XMLSchema#string

P921

P932

4256120

http://www.w3.org/2001/XMLSchema#string